Online Oncology CME | 13 Sessions Available Now

Dr. Michael W. Schuster, M.D., is a renowned hematologic cancer expert known for spearheading the development of two of New York’s largest bone marrow and stem cell transplantation programs, who currently serves as Professor of Medicine, Stony Brook University School of Medicine, Director of Hematologic Malignancies and Director of Bone Marrow and Blood Stem Transplantation at Stony Brook University Hospital. Dr. Schuster leads the institution in expanding treatment and bone marrow/stem cell transplantation options for patients with leukemia, lymphoma and other hematologic malignancies. Prior to Stony Brook, Dr. Schuster served as founding director of Bone Marrow and Blood Stem Cell Transplantation for 12 years at New York Presbyterian Hospital/Weill Cornell Medical College. Prior to that, he founded the adult stem cell transplant program at North Shore University Hospital in Nassau County. A graduate of Dartmouth Medical School, Dr. Schuster completed his training in Hematology/Oncology at Beth Israel Hospital in Boston and a Postdoctoral Fellowship in Molecular Biology at Harvard University. He is board certified in Internal Medicine and Hematology and is a member of numerous professional and scientific societies, including the American Society of Hematology, American College of Physicians, American Society of Clinical Oncology, New York Academy of Sciences, American Society of Bone Marrow and Stem Cell Transplantation, and the Bone Marrow Foundation.

William Sharfman, MD is an Associate Professor of Oncology and Dermatology at The Johns Hopkins University School of Medicine. In addition, Dr. Sharfman is also the Director of Cutaneous Oncology at The Sidney Kimmel Comprehensive Cancer Center. He completed his residency and fellowship at the Cleveland Clinic in Cleveland, OH and is board certified in hematology, medical oncology, and internal medicine.

Dr. Karp currently serves as Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. A board-certified oncologist, Dr. Karp is an authority on the molecular mechanisms of leukemias and lymphomas with a primary clinical interest in the experimental therapeutics of acute leukemias. She serves as the Director of the Leukemia Program within the Division of Hematologic Malignancies and is Co-Principal investigator (with Dr. Michael Carducci and Michelle Rudek) of the NCI Cooperative Agreement (U01) grant for early drug development. She is responsible for the clinical direction of the Heme 2 inpatient leukemia service and the portfolio of early phase clinical trials of new agents with unique mechanisms of action for adult acute leukemias and high-risk myelodysplasia (MDS). Dr. Karp studied at Stanford University School of Medicine and completed her residency and fellowship at John Hopkins.

Carol Ann Huff, MD is an Assistant Professor of Oncology and Medicine and Director of the Myeloma Program in the Division of Hematologic Malignancies at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. Prior to receiving her medical degree from Baylor College of Medicine, Dr. Huff completed a Bachelor of Science in Zoology at Duke University in Durham, NC. She completed her internship, residency and chief residency at the Johns Hopkins University School of Medicine. From there, she joined the faculty as an Assistant Professor of Medicine. She went on to complete a clinical fellowship in Oncology before formally accepting a joint appointment in the Oncology department. Dr. Huff’s research interest and expertise is in clinical translational research, bringing promising findings from the laboratory to patients with a particular emphasis on developing new biologically-based therapies for myeloma in particular to target myeloma stem cells and to enhance immune-based approaches.

Andrew J. Armstrong, MD, ScM, is co-program leader of the genitourinary oncology research program, part of the oncology clinical trials shared resource of the Duke Comprehensive Cancer Center. Armstrong is an internationally recognized expert in prostate cancer outcomes studies in men with castration-resistant metastatic disease, including nomograms and risk group models on prognosis. His research is focused on the development of experimental therapeutics in advanced prostate cancer, particularly those targeting the PI3 kinase/mTOR pathways, as well as the development of prognostic and predictive biomarkers of treatment efficacy, particularly with a focus on circulating tumor cell biology and epithelial-mesenchymal transition (epithelial plasticity). Armstrong is a recipient of a Prostate Cancer Foundation Young Investigator Award (2008-2011), an American Society of Clinical Oncology Young Investigator Award (2005-2008), an American Association for Cancer Research Clinical and Translational Fellowship (2005-2008), and has received a Department of Defense Prostate Cancer Research Program Physician Research Training Award (2010-2015).

Dr. Armstrong is an associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and an associate professor in gynecology and obstetrics at the Johns Hopkins University School of Medicine. Dr. Armstrong also directs the Johns Hopkins Breast and Ovarian Screening Service, a genetic counseling service that focuses on identifying patients at risk for cancer and examination of new strategies for cancer screening and prevention. Dr. Armstrong has lectured locally, nationally and internationally. She is active in the Gynecologic Oncology Group, serving on the Medical Oncology, Developmental Therapeutics and Phase I GOG committees and as chair of several clinical trials through this group. She is a representative of the Southwest Oncology Group to the Gynecologic Cancer Steering Committee of the National Cancer Institute.

Dr. Michael J. Borowitz is an internationally renowned hematopathologist with particular expertise in the flow cytometric diagnosis of hematologic malignancies. He has been a leader in numerous organizations concerned with the clinical application of this technology. Dr. Borowitz is one of the leaders in applying immunologic techniques to diagnose and classify leukemia and lymphoma. He has published numerous articles documenting the importance of these ancillary studies in the accurate diagnosis of these cancers, and has been particularly active in applying sophisticated approaches using the technique of flow cytometry. He has also been a leader in standardizing the practice of flow cytometry as it applies to leukemia and lymphoma, and has worked on developing improved proficiency testing programs and guidelines as well as good laboratory practice.

Dr. Brodsky's major clinical research involves the study of aplastic anemia, PNH and other bone marrow failure disorders. His research shows that immunoablative doses of cyclophosphamide, without bone marrow transplantation, can lead to durable complete remissions in severe aplastic anemia. The reason high-dose cyclophosphamide is able to ablate the effector cells without destroying hematopoietic stem cells is that the earliest stem cells (but not lymphocytes) contain high levels of aldehyde dehydrogenase conferring resistance to the cytoxic properties of cyclophosphamide. Dr. Brodsky and his colleagues in neurology and rheumatology are applying this approach in other severe autoimmune disorders including, scleroderma, myasthenia gravis, multiple sclerosis and autoimmune hematologic disorders.

Dr. Brown is Assistant Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. He is an expert in the diagnosis and treatment of cancer in children and young adults. His primary area of expertise is in the area of blood cancers, including leukemia and lymphoma. He is a leader within the international Childrens Oncology Group (COG) consortium, having been appointed to the executive steering committee for both the Acute Lymphoblastic Leukemia (ALL) and the Myeloid Disorders Committees. He is the principal investigator of two active COG clinical trials for leukemia. He is also a member of the POETIC pediatric phase I consortium, which is investigating novel targeted agents in childhood cancer. Based on this work, Dr. Brown is now leading the first clinical trials of a FLT3 inhibitors combined with chemotherapy in children with leukemia through the Childrens Oncology Group international network.

Michael A. Carducci, MD, is a Professor of Oncology and Urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore Maryland. He is Co-Leader of the Prostate Cancer / Genitourinary Oncology Program and Co-Leader of the Chemical Therapeutics Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. A translational researcher, Dr. Carducci directs a laboratory program focused on the re-expression of epigenetically silenced genes in cancer cells via the use of small molecules targeting DNA methyltransferases and histone deacetylases, and manages a portfolio of clinical trials targeted at introducing these small molecules into cancer treatment. Overall, his laboratory and clinical research focus is on the development and evaluation of new therapies for urologic cancers.

Dr. Chung joined the Division of Hematology/Oncology at Vanderbilt University's Department of Medicine in July of 2003. Her primary research focus is in preclinical and correlative studies of novel therapeutics for the treatment of head and neck cancer. Traditional approaches to identify genes and proteins that predict biological and clinical behavior of the tumors have included multiple techniques designed to examine one, or at most, a handful of genes at a time. Comprehensive analyses of gene and protein expression patterns of individual tumors can be achieved with genomics and proteomics, which allow to study up to 20,000 human genes at once. Her laboratory will investigate the identification of markers for disease outcome and predictors of conventional and novel treatment responses using these innovative techniques.

Dr. Ezra Cohen specializes in head and neck, lung, and esophageal cancers. He is an expert in novel cancer therapies and has done extensive research in molecularly targeted agents in the treatment of these cancers. His research interests also include radiation therapy for non-small cell lung cancer and squamous cell carcinoma of the head and neck, and especially ways to combine radiotherapy with novel agents. Dr. Cohen has developed an expertise in head and neck cancer resulting in lecture invitations at scientific meetings around the world, numerous publications, and prestigious awards.

Jeffrey Crawford, MD, is George Barth Geller Professor for Research in Cancer and Chief of Medical Oncology at Duke University Medical Center in Durham, North Carolina. Dr Crawford earned his medical degree from Ohio State University and completed his internship, residency, and hematology/oncology fellowship at Duke University Medical Center. He was Chief Resident in medicine and also completed a fellowship in geriatrics at Veterans Administration Medical Center in Durham, North Carolina. Dr Crawford is board certified in internal medicine, hematology, and oncology. His research interests include new treatment approaches for lung cancer, supportive care therapies, and clinical trials of hematopoietic growth factors, biological agents, and targeted drug development. He is Co-Leader of the multidisciplinary Albert Thoracic Oncology Program, with a particular focus on genomic approaches to understand the biology and direct treatment for patients with lung cancer.

Dr. Myron S. Czuczman joined the staff of Roswell Park Cancer Institute in 1992, as attending physician, Department of Medicine, and was appointed Head of the Lymphoma/Myeloma Service in 1998. He also is an Associate Professor of Medicine at the University at Buffalo (UB) School of Medicine and Biomedical Sciences. Dr. Czuczman serves on the medical staff at Buffalo General Hospital and as an Adjunct Faculty member at D’Youville College in Buffalo, NY. Dr. Czuczman earned his medical degree from Pennsylvania State University College of Medicine in 1985. He completed internship and residency training at Cornell’s North Shore University Hospital/Memorial Sloan-Kettering Cancer Program (1985-1988). Between 1988 and 1992, Dr. Czuczman completed a fellowship in Medical Oncology/Hematology and a senior research fellowship in Hematopoietic Cancer Immunochemistry at Memorial Sloan-Kettering Cancer Center, New York, NY.

Luis Diaz, M.D., is director of translational medicine at the Ludwig Center for Cancer Genetics and Therapeutics at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Dr. Diaz’s clinical interests include gastrointestinal cancers including colorectal cancer and pancreatic cancer. The focus of Dr. Diaz’s research is two-fold: The first is translating novel and often high-risk therapeutics with unique mechanisms of action from the lab to patients.This approach, termed bacteriolytic therapy, is being testing in clinical trials at Johns Hopkins and the University of Pennsylvania in humans and canines with advanced solid tumors. His second area of research includes a novel test that measures tumor-derived DNA in the bloodstream. Dr. Diaz received his medical degree from the University of Michigan Medical School, and completed his general medicine training at Johns Hopkins followed by a fellowship in Medical Oncology at the Johns Hopkins Kimmel Cancer Center.

Dr. Ghosh focuses his rearch on clinical translational investigation in myeloma and development of clinical protocols. His biological science background coupled with strong clinical skills makes him an indivual ideally suited for this role. He has designed a clinical trial to evaluate the role of Phosphodiesterase 5 inhibitors, such as tadalafil, in multiple myeloma. This clinical trial is currently under review by the Johns Hopkins IRB. He is also in the process of developing clinical protocols to study the role of PARP inhibitors in multiple myeloma and lymphomas. He was recently rewarded the American Society of Clinical Oncology Young Investirgator award and the Leukemia and Lymphoma Society Special Fellow in Clinical research award. In addition to his clinical research responsibilities, Dr. Ghosh attends on the in-patient hematologic malignancy services, maintains an outpatient clinic for myeloma and lymphoma, recruits patients on clinical protocols and is actively involved in trainging clinical fellows, residents and medical students.

Dr. Gladstone is an Associate Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He completed his Internal Medicine Internship, Residency and Chief Residency at the University of Rochester, Rochester New York. He subsequently completed his Hematology and Oncology Fellowship training at the John Hopkins Medical Center in Baltimore, M.D., specializing in hematologic malignancies. After fellowship training, Dr. Gladstone was an Assistant Professor of Medicine and Pathology at Drexel University, Philadelphia, PA. There, Dr. Gladstone was the Director of Research for the Division of Hematology and Oncology and was indoctrinated in the 106 Club for developing new Prostate Cancer treatment strategies. He subsequently founded and served as Co-Director of the Bone Marrow Transplant unit at Stony Brook University. Dr. Gladstone is an active researcher and physician educator. His articles have appeared in national and international Hematologic and Neurologic journals. He was recently listed in the Best Doctors in America.

Jack Goldberg, MD serves as Chief of the Division of Hematology and Oncology of the University of Pennsylvania Health System, Presbyterian Medical Center. Dr. Goldberg serves as Head of the New Jersey Pain Initiative and continues to be active in research in hematopoiesis. Dr. Goldberg has been a Consultant to the National Cancer Institute. He served as Medical Director of CorCell Inc. (which is now a Cord Blood America subsidiary) since 1996. He served as the head ... of Cooper Cancer Institute and the Division of Hematology and Medical Oncology of the Cooper Health System since 1989. Dr. Goldberg also served as Medical Director of the Coagulation Laboratory, the Adult Hemophilia Center. He serves as the Chairman of Scientific and Medical Advisory Board of CorCell Inc. Dr. Goldberg has been Chairman of Medical Advisory Board of Cord Blood America Inc. since May 3, 2007. He returned to SUNY Health Science Center in Syracuse and completed his fellowship in hematology and medical oncology.

Dr. William J. Gradishar is Professor of Medicine in the Division of Hematology and Medical Oncology at the Feinberg School of Medicine at Northwestern University. His research focuses on the development of the latest therapies for breast cancer treatment. He has published numerous articles in the area of breast cancer therapy, with a focus on new endocrine therapy and chemotherapy. He received his medical degree from the University of Illinois Abraham School of Medicine and completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center. He then went on to a fellowship in medical oncology at the University of Chicago. Dr. Gradishar is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He also serves as director of breast medical oncology, associate director of the Lynn Sage Comprehensive Breast Program, and program director of Northwestern University's Hematology/Oncology Fellowship Training Program.

Dr. Claudia Henschke is a Professor of Radiology and heads the Lung and Cardiac Screening Program at the Mount Sinai Medical Center. A pioneer and leading expert in the field of diagnostic radiology, Dr. Henschke has long believed that smokers and former smokers should consider being tested with low-dose CT scans to detect lung cancer when a tumor is still small enough to be cured. Dr. Henschke has more than 20 years of clinical and research experience in this area and , since 1993, has led city, state, national, and international projects that have resulted in the diagnosis of some 800 lung cancers. She and her team have created a protocol that has set an international standard for performing low-dose CT scans and managing findings which require additional testing. Dr. Henschke heads the International Early Lung Cancer Action Program (I-ELCAP) which is an international collaborative group consisting of experts on lung cancer related issues. More than 60 sites in the world have participated in this research program.

Dr. Hudis is a medical oncologist and Chief of the Breast Cancer Medicine Service and attending physician at Memorial Sloan-Kettering Cancer Center in New York City, where he is also a professor of medicine at the Weill Medical College of Cornell University. He is co-leader of the Breast Disease Management Team at MSKCC, co-chair of the Breast Committee of the Cancer and Leukemia Group B (CALGB), past chair of the Internet Services Committee and present chair of the Information Technology Committee of the American Society of Clinical Oncology (ASCO). He is also past president of the New York Metropolitan Breast Cancer Group and chair of the Scientific Advisory Board of the Breast Cancer Research Foundation. His research interests include chemotherapy development, hormone therapy, novel targeted therapeutics, and supportive care. He is a member of the Breast Committees of the Radiation Therapy Oncology Group and the National Comprehensive Cancer Network.

Dr. Stephen Hunger is Associate Director at the University of Colorado Cancer Center and the section chief of cancer and blood disorders at The Children's Hospital (of Colorodo), with a specific area of interest in leukemia. He is also professor of pediatrics at the University of Colorado Denver School of Medicine. He is also the Ergen Family Chair in Pediatric Cancer, chair of Acute Lymphocytic Leukemia Disease Committee and the Children's Oncology Group at The Children's Hospital.

Dr. Jackman received his medical degree from Brown University School of Medicine in 2000. He subsequently completed his residency in Internal Medicine at Beth Israel Deaconess Medical Center and his fellowship in Medical Oncology at Dana-Farber/Partners CancerCare. He currently works in the Lowe Center for Thoracic Oncology. His current clinical research interests are focused on clinical and molecular predictors of response to drugs that target the epidermal growth factor receptor in non-small cell lung cancer.

Dr. Lisa Jacobs is an Assistant Professor of Surgery at the Johns Hopkins University with a clinical practice encompassing Breast Cancer and Melanoma. She is fellowship trained in Surgical Oncology and has practiced Surgical Oncology since 2000. Her initial practice was at the University of Missouri at the Ellis Fischel State Cancer Center which is the designated cancer center for the state. She subsequently moved to Johns Hopkins University in 2004 to focus her practice on Breast Cancer and Melanoma. At Johns Hopkins University she is the Director of Clinical Breast Cancer Research with faculty appointments both the departments of Surgery and Oncology.

Howard L. Kaufman, MD, is director of the Rush University Cancer Center at Rush University Medical Center. Kaufman is also an associate dean of Rush Medical College and a professor in the departments of general surgery, internal medicine, and immunology and microbiology. After receiving his medical degree from Loyola University Chicago Stritch School of Medicine, Kaufman completed a residency in general surgery at Boston University. He followed with fellowships in tumor immunology and surgical oncology at the National Cancer Institute in Bethesda, Md. Kaufman brings a wealth of experience in the management of a large cancer enterprise to his role as director of the Rush University Cancer Center. He has served as chief of the Division of Surgical Oncology and director of the Melanoma Center at Columbia University Medical Center in New York. Prior to that, he served as associate director of the Herbert Irving Comprehensive Cancer Center at Columbia and co-chaired the oncology service line at New York Presbyterian Hospital.

Mark G. Kris, MD, FACP, FACCP, specializes in thoracic cancer as Chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center and is a Professor of Medicine at Weill Cornell Medical College. His research focuses on the development of biology-based treatments that specifically attack lung cancer, multimodality therapies, and drugs to control physical symptoms caused by cancer and its treatment. Dr. Kris is the current Chair of ASCO’s Cancer Communications Committee, Co-Chair of the CCO-ASCO Adjuvant Therapy for Stages I-IIIa Lung Cancer Panel, and a member of the Anti-Emetics Panel and Timely Oncology Perspectives Task Force. Among his accolades are a 2010 ASCO Statesman Award and an American Cancer Society Clinical Oncology Career Development Award.

Dr. Laheru currently serves as an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Laheru specializes in gastrointestinal oncology with a specific focus in pancreatic cancer. His clinical research interests are in developing and testing new therapies for the treatment of pancreatic cancer. He has developed a clinical trial program to optimize a vaccine approach using GM-CSF transfected pancreatic cell lines as a vaccine in two distinct patient populations. He has also incorporated correlative studies that should provide important information to better understand optimal vaccine boosting schedules as well as to identify antigens that can be predictive in-vitro markers for anti-tumor immune responses. Dr. Laheru is investigating mechanisms of chemotherapy resistance in pancreatic cancer and will be developing and testing new targets for therapy in patients with metastatic pancreas cancer.

Dr. Nicole Lamanna, MD is a medical hematologist and oncologist who specializes in the treatment of adult patients with acute and chronic leukemias. Her clinical research focuses on developing new and more-effective treatments for patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

Dr. Lange is a graduate of the Vanderbilt University School of Medicine and completed her general surgery training at Yale-New Haven Hospital. She completed a fellowship in surgical oncology and immunotherapy at the Surgery Branch of the National Cancer Institute as well. Dr. Lange joined the faculty of the Department of Surgery at Johns Hopkins in 1994 and subsequently earned a Sc.M. in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. Clinically her focus is on the care of melanoma and breast cancer patients. Dr. Lange was one of the original members of the Melanoma Group at Hopkins when it was first formed in 1995 and now serves as a clinical co-director of the Melanoma Program. Dr. Lange introduced the sentinel node technique to Hopkins for both melanoma and breast cancer in the 1990s and has extensive experience with this technique.

Evan Lipson, M.D., is a melanoma specialist at the Johns Hopkins Kimmel Cancer Center. His research focuses on investigating new therapies for patients with various stages of melanoma, ranging from preventing disease recurrence in high-risk patients to developing innovative drug therapies for patients with advanced disease. Dr. Lipson is also the founder of Seize the Days.org, which chronicles the stories of cancer patients who, with power and determination, battle an aggressive disease.

Terry P. Mamounas, MD, is Professor of Surgery at Northeastern Ohio Universities College of Medicine and Medical Director for the Aultman Cancer Center in Canton, Ohio. He is also Chairman of the Breast Committee at the National Surgical Adjuvant Breast and Bowel Project (NSABP) in Pittsburgh, Pennsylvania. Dr. Mamounas received his medical degree from the University of Athens Medical School in Athens, Greece, and a Masters of Public Health degree in Epidemiology from the University of Pittsburgh. He completed his surgical residency at McKeesport Hospital in McKeesport, Pennsylvania, an oncology research fellowship at the University of Pittsburgh and a surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, New York. Dr. Mamounas serves on the Board of Directors of the NSABP and the American Society of Breast Disease, serves on the editorial boards of Annals of Surgical Oncology and Women’s Health, and is associate editor for the Journal of Clinical Oncology.

Vincent A. Miller, MD, is an Associate Attending Physician on the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center and Associate Professor of Medicine at Weill Medical College of Cornell University. Dr. Miller’s main research focus is on drug development and the treatment of non–small cell lung carcinoma. Dr. Miller has received both the prestigious American Cancer Society Clinical Oncology Career Development Award and the Louise and Allston Boyer Award. Dr. Miller currently serves as a Track Leader in Lung Cancer for the ASCO Cancer Education Committee. Dr. Miller received his M.D. at the University of Medicine and Dentistry of New Jersey in Newark. He completed an internship and residency and then served as Chief Medical Resident in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, and subsequently a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center.

Dr. Morris is a board-certified medical oncologist who specializes in treating men with prostate cancer, particularly those who have metastatic disease or who are at high risk of developing metastatic disease. He is currently involved in the development of the Prostate Cancer Clinical Trials Consortium (PCCTC), an initiative designed to increase patient access to clinical trials across the country. Dr. Morris is also on Cancer and Leukemia Group B (CALGB)’s genitourinary committee, a National Cancer Institute-designated group composed of local and academic oncology centers, to facilitate clinical testing of new drugs throughout the country. In addition, he is very involved with the American Society of Clinical Oncology (ASCO), ASCO's Education Committee and is chair of the Genitourinary Scientific Track.

Dr. Morton is an accomplished surgical oncologist and a renowned clinical scientist whose fundamental discoveries have profoundly changed the treatment of human cancer. His pioneering work with intratumoral bacille Calmette-Guerin for melanoma represented the first successful clinical application of immunotherapy against a metastatic human cancer. His innovative studies of sentinel node mapping changed the standard of care for patients with early-stage malignant melanoma and other solid cancers that drain via the lymphatic system. Dr. Morton has received NIH peer-reviewed research funding for 35 years. Dr. Morton’s scientific contributions towards the immunology of cancer and surgical oncology have yielded more than 600 publications in peer-reviewed journals and have garnered him a long series of prestigious awards and honors. Dr. Morton is the past president of the International Sentinel Node Society, past president of the Society of Surgical Oncology, and past president of the World Federation of Surgical Oncology Societies.

Dr. Nelson is the Marion I. Knott Professor of Oncology and Director of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Nelson is also a Professor of Urology, Pharmacology, Medicine, Pathology, and Radiation Oncology at the Johns Hopkins University School of Medicine, with a Joint Appointment in Environmental Health Sciences at the Johns Hopkins University Bloomberg School of Public Health. In addition to his administrative duties, he directs a research laboratory focused on discovering new strategies for prostate cancer treatment and prevention. He is also the Principal Investigator for the National Cancer Institute (NCI)-funded Molecular Targets Training Program, dedicated to providing clinical oncology fellows specific training in translational research, and for the NCI-supported Prostate Cancer SPORE Program, a multidisciplinary research effort for translational research targeting new approaches to prostate cancer detection, diagnosis, prevention, and treatment.

Dr. S. Vincent Rajkumar is a professor of medicine at the Mayo Clinic in Rochester, Minnesota. His research focuses on clinical, epidemiological, and laboratory research for myeloma and related disorders. Dr. Rajkumar writes a quarterly column for The Myeloma Beacon.

Aaron P. Rapoport, MD, is a Professor of Medicine at the University of Maryland School of Medicine and Director of Gene Medicine and Lymphoma at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. Dr. Rapoport received his medical degree from Harvard Medical School, completed his residency at Strong Memorial Hospital and the University of Rochester, and his fellowship in Hematology and Blood and Marrow Transplantation at the University of Rochester School of Medicine. His research is focused on immunotherapy for blood cancers in patients who undergo autologous stem cell transplants. Dr. Rapoport has been studying whether T-cells from patients with CML and myeloma can be activated in the laboratory and returned to patients after transplantation in order to help fight their disease. Currently he is developing new post-transplant strategies that combine activated T-cells and cancer vaccines.

Alice T. Shaw, MD, PhD is an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, an assistant professor of medicine at Harvard Medical School, and a clinical investigator at MIT’s Koch Institute for Integrative Cancer Research. In addition to caring for patients with lung cancer, Dr Shaw also performs clinical and translational research. Dr Shaw’s major research interests include studying anaplastic lymphoma kinase (ALK) translocations in non-small cell lung carcinoma (NSCLS); developing targeted strategies to treat NSCLCs harboring activating KRAS mutations; discovering new targets in NSCLC using both genetic and phosphoproteomic strategies; and developing novel nanoparticle-based siRNA delivery systems to target genetically defined subsets of lung cancer.

Dr. Wendy Stock is a Professor of Medicine at University of Chicago Comprehensive Cancer Center. She is an authority in the medical management of all types of leukemia and myelodysplastic syndromes. She collaborates with other oncologists around the world through the National Cancer Institute and the Cancer and Leukemia Group B to help identify and develop better approaches to chemotherapy and other cancer treatments. Dr. Stock's laboratory focuses on studies to determine the clinical significance of the molecular detection and monitoring of minimal residual disease (MRD) states following treatment for leukemia and lymphoma. The laboratory is a national reference laboratory for several of these studies. Dr. Stock is also developing novel technology to measure tyrosine kinase activity in leukemia cells as a method for predicting response to treatment with novel targeted kinase inhibitors. She serves on the editorial board of the Journal of Clinical Oncology and has published papers and reviews in many esteemed medical journals.

In September 2003, Sabine Tejpar became an Associate Professor in the Dept of Gastro Enterology, Digestive Oncology Unit, UZ Leuven. Prior to this, she completed training in Internal medicine and Gastro Enterology and a PhD in the program of Molecular Oncology at the Center for Human Genetics, KU Leuven. Prof. Tejpar, works part time as a clinician and researcher (Senior Clinical Investigator of the Fund for Scientific Research-Flanders, Belgium), with a focus on basic and translational research in colorectal cancer. Her main research projects involve prognostic markers in adjuvant colorectal cancer and predictive markers for efficacy of EGFR inhibition.

Dr. Vogelstein obtained his medical degree at the Johns Hopkins University School of Medicine and performed his internship and residency in pediatrics at the Johns Hopkins Hospital. Following his clinical training, Dr. Vogelstein completed a post-doctoral fellowship at the National Cancer Institute, focusing on the development of new techniques in molecular biology. He returned to Johns Hopkins as an Assistant Professor in Oncology, and is now Clayton Professor of Oncology and Pathology. Dr. Vogelstein also holds a joint appointment in Molecular Biology and Genetics at JHU and is an Investigator of the Howard Hughes Medical Institute. He was recently appointed Director of the Ludwig Center for Cancer Genetics & Therapeutics at the Johns Hopkins Kimmel Cancer Center.

Dr. Weitz is an Associate Professor of Clinical Medicine at the Keck-USC school of Medicine. She completed her medical school training at the Medical College of Pennsylvania, Internal Medicine residency at Cedars-Sinai Medical Center in Los Angeles and Hematology fellowship at Scripps Clinic and Research Foundation, in La Jolla, CA. She is a member of Alpha Omega Alpha Honor Society and the recipient of the Morris Press Humanism award, the Golden Apple teaching award from Cedars Sinai Medical Center, as well as the Hematology Voluntary Faculty teaching award from USC. Her specific interests include “benign” hematologic disorders, and thrombosis /hemostasis. She published several papers and chapters on “Cancer and thrombosis”, “Thrombosis in PNH” “Hematologic disorders in the elderly”, “DIC”, ACP on line management algorithm for the treatment of Hemophilia. She has lectured extensively about PNH and in particular thrombosis in PNH.